Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chronic Myeloid Leukemia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03831776
- Collaborators
- Haukeland University Hospital
- Oslo University Hospital
- University Hospital of North Norway
- Helse Stavanger HF
- Henri Mondor University Hospital
- Hôpital René Huguenin
- Hôpital Mignot, Versailles Paris
- Uppsala University Hospital
- Odense University Hospital
- Investigators
- Study Director: Tom Christian Martinsen, md phd St Olavs Hospital, Clinical of Internal Medicine Principal Investigator: Henrik Hjorth-Hansen, md phd St. Olavs Hospital Principal Investigator: Lydia Roy, md phd Centre Hospitalo-Universitaire Henri Mondor, Service d'Hematologie Clinique
Get Well Soon